Genetics & Genomics 2019

COVID-19 represents a global crisis, yet significant knowledge gaps remain about human immunity to SARS-CoV-2. As many researchers raced to develop the vaccines and therapeutics needed to mitigate the pandemic, other investigators took up the task of understanding the human body’s diverse response to this virus. With technology advancing exponentially, researchers have an arsenal of analytic tools now at their disposal to decipher the most elusive aspects of viral immunobiology.

When assessing a potential biological therapeutic candidate, several histopathological technologies are typically employed. This ensures the target expression is validated in both normal and diseased tissues before proceeding with pre-clinical studies. Protein B is a transmembrane glycoprotein that is overexpressed in numerous cancers, including triple-negative breast cancer and is often correlated with the metastatic phenotype. In this GEN webinar, we will discuss the process involved in a typical molecular pathology laboratory. Control cell lines and the RNAScope® Assay were utilized to validate the immunohistochemistry protocol.

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) supports a large network of National Centers for Biomedical Imaging and Bioengineering (NCBIB) through the P41 grant mechanism.

Stem cell-based therapies require innovative solutions to close the gaps existing between research and commercialization. Allogeneic cell therapy indications that target large patient populations will necessitate the use of flexible cell production platforms to meet the increasing demand of cell quantities. In addition, process control and monitoring, along with cell quality, are key parameters in clinical cell therapy product manufacturing. Human pluripotent stem cells (hPSCs) hold great promise for regenerative medicine and therefore, are a key intermediate cell therapy product.